Founder Lodge | Asher Biotherapeutics raises $55,000,000 at Series …

Apr 17, 2024  · Asher Biotherapeutics raises $55,000,000 at Series C on 2024-04-17 in Biotechnology Research, industry founded/co-founded by Craig Gibbs ... Series C; $55,000,000 ; Asher Bio is a biotechnology company developing precisely targeted immunotherapies for …


Install CouponFollow Chrome Extension   CouponFollow Extension

$55000000
OFF

Founder Lodge | Asher Biotherapeutics Raises $55,000,000 At Series …

3 weeks from now

Apr 17, 2024  · Asher Biotherapeutics raises $55,000,000 at Series C on 2024-04-17 in Biotechnology Research, industry founded/co-founded by Craig Gibbs ... Series C; $55,000,000 ; Asher Bio is a biotechnology company developing precisely targeted immunotherapies for …

founderlodge.com

$55
OFF

Asher Bio Closes $55 Million Series C Financing To Advance Lead …

3 weeks from now

Apr 16, 2024  · Asher Bio plans to use the proceeds from this financing to advance the clinical development of its lead program, AB248, a novel CD8+ T cell selective IL-2, generated by …

yahoo.com

$3
OFF

Founder Lodge | 225+ Founders $3.2B Raised’s Post - LinkedIn

3 weeks from now

Asher Biotherapeutics raised $55,000,000 in Series C-Congrats Craig Gibbs Full ... Founder Lodge | 225+ Founders $3.2B Raised’s Post ... Asher Biotherapeutics raised $55,000,000 in …

linkedin.com

$55
OFF

Asher Bio Closes $55 Million Series C Financing To Advance

3 weeks from now

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and …

nasdaq.com

$55
OFF

Asher Bio Secures $55M In Series C Funding For Cancer Therapy

3 weeks from now

Apr 18, 2024  · Asher Biotherapeutics raises $55 million in Series C funding led by RA Capital, with AstraZeneca and Bristol Myers Squibb among new investors. ... The successful closing of …

sliceofhealthcare.com

$55
OFF

Asher Bio Launches With $55 Million Series A Financing Led By …

3 weeks from now

Mar 23, 2021  · – Cis-targeting technology aims to enable precise targeting of discrete beneficial immune cell subtypes with a novel class of biotherapeutics and avoid unwanted effects driven …

asherbio.com

$55000000
OFF

Asher Biotherapeutics - Founder Lodge

3 weeks from now

Certified by Founder Lodge . Asher Biotherapeutics. Biotechnology Research, United States - South San Francisco , California . START UP . 1 Disclosed Funding Rounds $55,000,000 0 …

founderlodge.com

$55
OFF

Asher Bio Raises $55M In Series A Financing - FinSMEs

3 weeks from now

Mar 23, 2021  · Asher Biotherapeutics, a South San Francisco, Calif.-based biotechnology company developing precisely targeted immunotherapies for cancer and other diseases, …

finsmes.com

$16500000
OFF

Founder Lodge | Carefull Raises $16,500,000 At Series A On 2023-10 …

3 weeks from now

Oct 12, 2023  · Carefull raises $16,500,000 at Series A on 2023-10-12 in Financial Services, industry founded/co-founded by Todd Rovak

founderlodge.com

$143000000
OFF

Founder Lodge | CinCor Pharma, Inc. Raises $143,000,000 At Series …

3 weeks from now

Oct 12, 2021  · CinCor Pharma, Inc. raises $143,000,000 at Series B on 2021-10-12 in Biotechnology Research, industry founded/co-founded by Marc de Garidel

founderlodge.com

$55
OFF

Asher Bio Closes $55 Million Series C Financing To Advance Lead …

3 weeks from now

Apr 17, 2024  · South San Francisco - Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.. The financing was led by RA Capital Management, and included new investors AstraZeneca (LSE/STO/Nasdaq: …

marketscreener.com

$55
OFF

Asher Bio Launches With $55 Million Series A Financing Led By …

3 weeks from now

Mar 23, 2021  · Asher Bio’s team of founders, management and board members brings together leaders with accomplished track records in academia and in the biotechnology industry and …

businesswire.com

$80000000
OFF

Founder Lodge | A2 Biotherapeutics, Inc. Raises $80,000,000 At …

3 weeks from now

Jan 10, 2025  · A2 Biotherapeutics, Inc. raises $80,000,000 at Series C on 2025-01-10 in Biotechnology Research, industry founded/co-founded by Jim Robinson ... In addition to my …

founderlodge.com

$75
OFF

424B4

3 weeks from now

Pro forma amounts give effect to (i) the sale and issuance of Series D Preferred Stock subsequent to September 30, 2024 and the receipt of gross proceeds of $75.0 million …

sec.gov

$215000000
OFF

Founder Lodge | Metsera Raises $215,000,000 At Series B On 2024 …

3 weeks from now

Nov 14, 2024  · Metsera raises $215,000,000 at Series B on 2024-11-14 in Biotechnology Research, industry founded/co-founded by Whit Bernard

founderlodge.com

$75000000
OFF

Founder Lodge | Aloft VC Raises $75,000,000 At Series B On 2023 …

3 weeks from now

Jan 20, 2023  · Aloft VC raises $75,000,000 at Series B on 2023-01-20 in Venture Capital and Private Equity Principals, industry founded/co-founded by Crystal McKellar Daily News Rounds

founderlodge.com

$25000000
OFF

Founder Lodge | AtomicJar, Inc. Raises $25,000,000 At Series A On …

3 weeks from now

Jan 27, 2023  · AtomicJar, Inc. raises $25,000,000 at Series A on 2023-01-27 in Software Development, industry founded/co-founded by Sergei Egorov

founderlodge.com

$8000000
OFF

Founder Lodge | Tagboard Raises $8,000,000 At Series A On 2022 …

3 weeks from now

Feb 23, 2022  · Tagboard raises $8,000,000 at Series A on 2022-02-23 in Technology, Information and Internet, industry founded/co-founded by Nathan J Peterson Daily News Rounds

founderlodge.com

FAQs about Founder Lodge | Asher Biotherapeutics raises $55,000,000 at Series … Coupon?

What happened to Asher Biotherapeutics?

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of a Series C financing, raising $55 million. South San Francisco, Calif., April 16, 2024 ...

What is Asher Bio's AB248?

Asher Bio's lead program, AB248, is a novel CD8+ T cell selective IL-2. It was generated by fusing a reduced potency IL-2 mutein to an anti-CD8β antibody. Asher Bio plans to use the proceeds from this financing to advance the clinical development of AB248. ...

Who is Asher bio?

“Asher Bio has assembled a strong team, including two world-class academic founders in Ton Schumacher and Robert Schreiber, to execute on a big vision – to develop an entirely new biotherapeutic class to harness the therapeutic power of cytokine immunotherapies. ...

What makes Asher bio unique?

Craig Gibbs, PhD, Chief Executive Officer of Asher Bio, said, “Our founders had the insight to focus on designing immunotherapies that would only have their effect on defined immune cell subtypes rather than trying to localize the effect of inherently non-specific molecules. ...

Is Asher bio a breakthrough cytokine immunotherapy solution?

Jeffrey Tong, PhD, Partner at Third Rock Ventures said, “Following an exhaustive assessment of the cytokine immunotherapy landscape, Third Rock is excited to partner with Asher Bio and their unique approach, which we believe has breakthrough potential to generate multiple differentiated product candidates.” ...

Where is Asher bio located?

Asher Bio is backed by Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension